What are the best ways to monitor minimal residual disease in myeloid malignancies?

Melinda Tran, PharmD, BCOP
Kelda Gardner, PA-C, MHS

Melinda Tran, PharmD, BCOP, and Kelda Gardner, PA-C, MHS, on new directions in myeloid malignancies.

Copyright © 2010-2019 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.